Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Eyes 2008 NDA For DPP-4 Inhibitor Saxagliptin

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm also brokers licensing agreement with Otsuka for the diabetes candidate in Japan.

Related Content

Bristol-Myers Squibb Targets Mid-year Filing For Saxagliptin
Industry Eyes DPP-4, GLP-1 Data From Diabetes Meeting
Merck Builds On Januvia Momentum With Two Supplementary Claims
Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia NDA – FDA Review
Bristol Aims To Be First To Market With Novel Diabetes Drug Class
Bristol-Myers Squibb Latest To License DPP-4 Patents From OSI
Galvus Review Delayed For Safety Analysis Of Primate Skin Data
OSI Seeks Partner For DPP-4 Inhibitor Paused At Phase III Gate
DPP IV Inhibitor Januvia First Out Of The Gate
DPP IV Inhibitor Januvia First Out Of The Gate





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts